1 Interventions to reduce opioid use for patients with chronic non-cancer pain in

2

primary care settings: a systematic review and meta-analysis.

- ¹Qian Cai*, ²Christos Grigoroglou, ²Thomas Allen, ³Teng-Chou Chen, ³Li-Chia Chen,
- 4 ^{1,4}Evangelos Kontopantelis
- 5
- 6 ¹ Division of Informatics, Imaging & Data Sciences, School of Health Sciences,
- 7 Faculty of Biology, Medicine and Health, Manch6ester Academic Health Science
- 8 Centre, University of Manchester, Manchester, the United Kingdom.

² Centre for Health Economics, Division of Population Health, Health Services
Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine
and Health, Manchester Academic Health Science Centre, University of Manchester,
Manchester, the United Kingdom

- 13 ³ Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and
- 14 Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health,

15 University of Manchester, Manchester, the United Kingdom.

- ⁴ National Institute for Health and Care Research (NIHR) School for Primary Care
 Research, Division of Population Health, Health Services Research and Primary
 Care, School of Health Sciences, Faculty of Biology, Medicine and Health,
 Manchester Academic Health Science Centre, University of Manchester, Manchester,
 the United Kingdom.
- 21
- 22 *Corresponding author:
- 23 Qian Cai
- 24 Division of Informatics, Imaging & Data Sciences, School of Health Sciences, Faculty
- of Biology, Medicine, and Health, University of Manchester, Manchester, M13 9PL,
- 26 the United Kingdom

27 Phone: (0)7419737634

28 Email: qian.cai@manchester.ac.uk

29 Abstract

30 **Objective:** This systematic review and meta-analysis aimed to assess interventions
31 to reduce opioid use for patients with chronic non-cancer pain (CNCP) versus usual
32 care or active controls in primary care settings.

33 Methods: In this registered study (PROSPERO: CRD42022338458), we searched 34 MEDLINE, Embase PsycInfo, CINAHL, and Cochrane Library from inception to December 28th 2021, and updated on Dec 14th 2023 for randomized controlled trials 35 36 (RCTs) and cohort studies with no restrictions. Methodological quality was assessed 37 using the Cochrane Risk of Bias tool for RCTs and Newcastle Ottawa Scale for 38 cohort studies. Primary outcomes included mean reduction in morphine equivalent 39 daily dose (reported as mean differences [MDs] mg/day; 95% confidence intervals 40 [95%Cls]) and/or opioid cessation proportion. Secondary outcomes were mean 41 changes in pain severity (reported as standardized mean difference [SMDs]; 95%Cls) 42 and (serious) adverse events. Meta-analyses were performed using random-effects 43 models.

44 **Results:** We identified 3,826 records, of which five RCTs (953 participants) and six 45 cohort studies (967 participants) were included. Overall, opioid dosage was 46 significantly reduced in intervention groups compared to controls (MD: -24.88 mg/day, 47 95%CI: -36.40 to -13.36; I²=59.41%; nine studies). Subgroup analyses revealed 48 significant opioid dose reductions with mindfulness (MD: -29.36 mg/day 95%CI: -49 40.55 to -18.17; I²=0.0%; two trials) and CBT-based multimodalities (MD: -41.68 50 mg/day; 95%CI: -58.47 to -24.89; I^2 =0.0%; two cohort studies), respectively, 51 compared to usual care. No significant differences were observed in opioid cessation 52 (Odds ratio: 1.55, 95%CI: 0.3 to 2.81, I²=50.79%; three studies) or pain severity 53 (SMD: -0.13, 95%CI: -0.37 to 0.11; I²=33.51%; three trials). Adverse events were 54 infrequently examined, with withdrawal symptoms commonly reported.

55 **Conclusions:** The studied interventions were effective in reducing opioid dosage for 56 people with CNCP in primary care. They highlighted the importance of

57 multidisciplinary collaboration. Large-scale RCTs measuring the long-term effects58 and cost of these interventions are needed before their implementation.

59

60 Introduction

61 Opioids are primarily recommended by the World Health Organization pain ladder in 62 treating acute pain, cancer pain, and palliative care [1]. During the last two decades, 63 there has been a marked increase in opioid prescriptions issued for chronic non-64 cancer pain (CNCP), predominantly in the United States (US) [2], Canada [3], and 65 several European countries [4-6] including the United Kingdom (UK) [7]. Despite the 66 widespread utilization of opioids, findings from randomized controlled trials and 67 systematic reviews suggest limited efficacy of these medications, yielding only 68 modest effects in pain relief in the short to medium term (less than 12 weeks) [8]. 69 While the evidence supporting the long-term use of opioids remains sparse, the 70 associated harms of long-term opioid treatment (LTOT), including respiratory 71 depression, bone fractures, and opioid-related mortality, are well documented [9]. 72 Moreover, prolonged opioid use introduces risks of dependence, addiction, and 73 abuse [10].

74

75 In response to these concerns, clinical guidelines [11-13] have prompted healthcare 76 providers (HCPs) to reassess their prescribing practices, emphasizing the need to 77 reduce opioid use when potential risks outweigh perceived benefits. However, the 78 endeavor to reduce opioid use encounters significant challenges, including patients' 79 fear of withdrawal symptoms, inadequate social and healthcare support, and limited 80 availability of non-opioid methods for pain management [14, 15]. Currently, there is a 81 lack of guidance and practical support to implement the reduction of LTOT. Therefore, 82 there is an urgent need for an evidence-based evaluation of interventions to assess 83 their effectiveness in reducing opioid utilization and evaluate their impact on clinical 84 outcomes, particularly in primary care settings, where opioids are mostly prescribed.

85

86 Previous systematic reviews [16-19] have provided valuable insights into 87 interventions aimed at reducing opioid use for chronic pain patients. However, their 88 inclusion criteria were broad, limiting their relevance to primary care settings. For 89 example, these reviews analyzed interventions (e.g., spinal cord stimulation) that are 90 not readily accessible in primary care settings, and they included studies that 91 evaluated abrupt or gradual opioid tapering protocols without incorporating additional 92 supportive therapies for patients. The provision of supplementary interventions is 93 crucial, as patients often express reluctance to reduce or cease opioids when 94 alternative treatments are not provided, given these medications constitute their 95 primary method of pain management in real-world practices. Furthermore, the 96 absence of additional interventions impedes the identification of the key components 97 contributing to the dose reduction outcomes. Some prior systematic reviews also 98 included pilot studies lacking clear objectives of opioid reduction. This is particularly 99 common for studies using pharmacological substitution, where the primary aim was 100 to address opioid withdrawal symptoms rather than reducing opioid dosage, despite 101 achieving a decrease in opioid dosage or an improvement in pain severity. In view of 102 these limitations and the emergence of new studies recently, there is a compelling 103 need for an updated evaluation of the current evidence.

104

105 The present systematic review and meta-analysis aimed to evaluate the 106 effectiveness of healthcare provider-directed interventions designed to reduce or 107 discontinue opioid use for patients with CNCP, with a particular focus on primary care 108 settings. Specifically, the objectives included comparing changes in morphine 109 equivalent daily dose (MEDD), evaluating the proportion of patients discontinuing 110 opioids, and assessing the change in pain severity and adverse events between 111 interventions and usual care or active controls.

112

113 Methods

This registered systematic review and meta-analysis (PROSPERO:
CRD42022338458) was conducted following the Cochrane Handbook [20] and the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines (S1 Appendix) [21].

118

119 Eligibility criteria

120 Eligible studies were full-scale randomized controlled trials (RCTs) and cohort studies 121 that examined primary care provider-directed interventions, designed to reduce or 122 discontinue opioids in adult patients (\geq 18 years) with CNCP (persists for \geq 3 months). 123 Studies that concurrently used opioids with other analgesics (e.g., non-steroidal anti-124 inflammatory drugs) were excluded, as distinguishing the analgesic effects of opioids 125 from those analgesics were challenging. Interventions implemented in hospital 126 settings or managed by patient themselves were not considered for inclusion. 127 Studies that solely focused on reducing opioids without offering patients alternate 128 treatments or replacements were excluded. Interventions were considered if they 129 explicitly aiming to reduce or cease opioid use, whereas those with a spillover effect 130 on opioid use were excluded. Any comparator was accepted, including usual care or 131 active controls (either pharmacological or non-pharmacological).

132

133 The primary outcomes of interest included: 1) opioid dose reduction, measured by 134 the mean changes in morphine milligram equivalent daily dose (MEDD) from pre- to 135 post-treatment. The homogeneity of this outcome measure allowed us to examine 136 our study objectives meta-analytically; 2) The proportion of participants for whom 137 opioid use was either ceased or declined. Secondary outcomes included the mean 138 change in pain severity (measured by pain rating scales on a range of 0-10, where 0 139 indicating no pain whilst 10 indicating severe pain) and the number of (serious) 140 adverse events related to opioid reduction. Case reports, cross-sectional studies,

141 case-control studies, pilot studies, reviews or meta-analyses were excluded.

142

143 Data sources and search strategies

144 We performed comprehensive searches in databases including MEDLINE, EMBASE, 145 PsycINFO, CINAHL, and Cochrane Central Register of Controlled Trials. Searches were conducted from the inception of each database until December 28th 2021, and 146 updated on December 14th 2023, using structured search strategies (S2 Appendix) 147 148 that incorporated text words and medical subject headings related to "chronic pain", 149 "opioids", and "reduce/discontinue/cease/deprescribe/". No language and geographic 150 restrictions were applied. Ongoing trials or unpublished studies were obtained from 151 ClinicalTrials.gov. To ensure literature saturation, we manually retrieved additional 152 studies from the reference lists of included studies and published systematic reviews.

153

154 Study selection

Two review authors (QC and CG) independently screened titles and abstracts of the retrieved citations against pre-determined inclusion/exclusion criteria. When necessary, full text of eligible records were reviewed for further eligibility assessment. Where discrepancies occurred and remained unresolved by discussion, a third party (EK, TA and LCC) was consulted for adjudication. The inter-rater agreement test demonstrated a high level of consistency (99.64%) between QC and CG with a Kappa coefficient equals to 0.7982 (p<0.001).

162

163 Data extraction and quality assessment

Data extraction was undertaken independently by one review author (QC) and verified by another reviewer (TCC) for accuracy. The study authors were also contacted by email to request any necessary missing information. The following key information was extracted:

• Study: first author, publication year, country, study design, settings.

- Patient characteristics: age, gender, sample size, pain duration and severity,
- 170 opioid use status, comorbidities.
- Intervention and comparator: key components, mode of administration,
 frequency, treatment duration.
- Outcome: opioid dose, pain severity, adverse events.
- 174

175 Risk of bias assessment

176 The methodological quality of all included studies was independently appraised by 177 QC. For RCTs, the Cohrane's Risk of Bias Tool 2.0 (RoB 2) [22] was employed to 178 assess the risk of bias, including 1. sequence generation; 2. allocation concealment; 179 3. masking of participants, staff and outcome assessors; 4. incomplete outcome data; 180 and 5. selective outcome reporting. For cohort studies, a modified Newcastle-Ottawa 181 Scale (NOS) [23] was used to evaluate bias risk, focusing on 1. the 182 representativeness of the exposed cohort; 2. selection of the non-exposed cohort; 3. 183 ascertainment of exposure; 4. absence of the outcome of interest at the start of the 184 study; 5. comparable controls; 6. assessment of outcome; 7. sufficient follow-up 185 length for outcomes to occur; and 8. adequacy of follow-up cohorts. For RCTs, high 186 quality was defined as minimum 4 domains of low risk. As for cohort studies, the 187 modified NOS adopted a star rating system. A study was deemed to be of good 188 quality if it obtained ≥ 3 stars in selection domain (1-4), ≥ 1 star in comparability 189 domain (5), and ≥ 2 stars in outcome/exposure domain (6-8).

190

191 Data synthesis and analysis

The study characteristics and details of opioid reduction interventions were presented descriptively. Effect sizes were reported using odds ratios (ORs) with their 95% confidence intervals (95%Cls) for opioid cessation, mean differences (MDs) with 95%Cls for opioid dose reduction, and standardized mean differences (SMDs) with 95%Cls for pain severity, given the utilization of different scales for this outcome

197 measure. Magnitude of effect was defined as large (SMD > 0.8), medium (SMD 0.5-

198 0.8), small (SMD 0.2-0.5) or trivial (SMD < 0.2) [24].

199

Where between- or within-group SDs were not reported, relevant data such as sample size, p values, t statistics, standard errors (SEs), or 95% Cls were used to derive SDs using the formula recommended by the Cochrane Handbook (6.5.2.3) [20] or the calculator embedded in Review Manager 5.4. Additionally, when outcomes were assessed at multiple time points during long-term follow-up, data from the last available time point were employed.

206

Heterogeneity was assessed using the l^2 statistics, with values below 50% suggesting low heterogeneity, 50-75% moderate, above 75% substantial heterogeneity [25]. Random effects meta-analyses with a non-parametric bootstrap of DerSimonian Laird (DL) method were conducted for pooling the outcomes of interest [26, 27] even if l^2 was low. Publication bias regarding the primary outcomes was not assessed due to the small number of included studies.

213

214 Sensitivity analyses were conducted by sequentially removing one study at a time 215 and repeating the meta-analysis based on the remaining data to assess whether 216 pooled estimates were unduly influenced by specific studies. Furthermore, 217 multivariable random effects meta-regressions were conducted to explore potential 218 sources of heterogeneity, including patient mean age; gender; study period; sample 219 size; follow-up time point; intervention type and category. Subgroup analyses were 220 undertaken based on intervention types, which included mindfulness techniques, and 221 CBT-based multi-component strategies. All data analyses were conducted with 222 Stata/MP 17.0.

223 Results

224 Study selection and patient characteristics

225 The initial search retrieved 3,826 potentially relevant records, of which 1,126 duplicates 226 were removed, yielding 2,770 unique records for eligibility assessment. By screening 227 titles and abstracts against our predefined inclusion/exclusion criteria, 2739 studies 228 were excluded. Of the remaining 31 records, eleven full-text articles including five RCTs 229 (953 participants, female 557 [58.4%], mean age: 60.1±13.42) [28-32] and six 230 retrospective cohort studies (patients 967, female 214 [22.1%], mean age: 54.2±13.52) 231 [33-38] published between 2016 and 2023 were included in this systematic review and 232 meta-analysis (Fig 1. Selection of included studies). All included studies reported the 233 baseline opioid dosage (mean 87.4±131.8 mg/day), with three [31, 33, 37] indicating 234 that participants consumed a mean MEDD of >120 mg/day. Most studies did not 235 specify the exact CNCP conditions, except for one study that explicitly mentioned 236 chronic musculoskeletal pain [38]. Studies were mainly conducted in the US (n=10), 237 with one in the UK [30]. Both RCTs and retrospective cohort studies had a small 238 sample size ranging between 35 and 608 (Table 1).

Table 1. Characteristics of included studies

Author, year and country	Study design	Population	interventions	Comparators	Outcomes of interest assessed	Quality	
Randomized controlled trials (n=5)							
Sandhu <i>et al.</i> 2023 [30], UK	Non-blind, two-arm, RCT	CNCP (n=608) female 362 (60%)	Skill-based learning integrating education and mindfulness (n=305)	Usual care (n=303)	 Opioid cessation Pain severity Adverse events	Good	
Wartko <i>et al.</i> 2023 [32], USA	Non-blind, two-arm, RCT	CNCP (n=153) female 98 (64%)	CBT-based pain coping skills training, education and usual care (n=79)	Usual care (n=74)	 Opioid dose reduction Pain severity Adverse events	Good	
Hudak <i>et al.</i> 2021 [29], USA	Non-blind, two-arm, RCT	CNCP (n=62) female 9 (14.5%)	The MORE protocol: Mindfulness (n=34)	The supportive care (n=28)	Opioid dose reduction	Good	
Garland <i>et al.</i> 2020 [28], USA	Non-blind, two-arm, RCT	CNCP (n=95) female 63 (66.3%)	The MORE protocol: Mindfulness (n=50)	The supportive care (n=45)	Opioid dose reduction	Fair	
Sullivan <i>et al.</i> 2017 [31], USA	Non-blind, two-arm, RCT	CNCP (n=35) female 25 (71.4%)	CBT-based multimodality & self- care & pain education (n=18)	Standard of care (n=17)	 Opioid dose reduction Opioid cessation Pain severity 	Fair	
Cohort studies (n=	=6)						
Montgomery <i>et al.</i> 2020 [35], USA	Retrospective cohort study	CNCP (n=47) female 5 (10.6%)	Acupuncture (n=24)	Standard of care (n=23)	 Opioid dose reduction Pain severity	Poor	
Seal <i>et al.</i> 2019 [37], USA	Retrospective cohort study	CNCP (n=294) female 30 (10.2%)	Integrated multimodality including CBT, mindfulness, pain education, acupuncture and exercise (n=147)	Standard of care (n=147)	Opioid dose reduction	Good	
Oldfield <i>et al.</i> 2018 [36], USA	Retrospective cohort study	CNCP (n=105) female 7 (6.7%)	Multimodality integrating CBT, exercise, and acupuncture (n=66)	Standard of care (n=39)	Opioid dose reduction	Good	
Goodman <i>et al.</i> 2018 [33], USA	Retrospective cohort study	CNCP (n=41) female 22 (53.7%)	Opioid reduction program & consultation with GPs (n=27)	Usual care (n=14)	Opioid dose reduction	Fair	

Author, year and country	Study design	Population	interventions	Comparators	Outcomes of interest assessed	Quality
Vigil <i>et al.</i> 2017 [38], USA	Retrospective cohort study	CMSK (n=66) female 26 (39.4%)	Medical cannabis & patient education (n=37)	Patient education (n=29)	 Opioid dose reduction Opioid cessation Pain severity	Fair
Mehl-Madrona <i>et al.</i> 2016 [34], USA	Retrospective cohort study	CNCP (n=414) female 124 (59.9%)	Medical care and physical exercise (n=207)	Standard of care (n=207)	Opioid dose reduction	Good

240 Note: CNCP=Chronic Non-Cancer Pain, CMSK=Chronic Musculoskeletal Pain, MORE=Mindfulness-Oriented Recovery Enhancement, CBT=Cognitive Behavioral Therapy,

241 GPs=general practitioner

242 Characteristics of interventions

243 The components, duration, frequency, and delivery mode of the interventions varied 244 significantly across studies. One study used medicine substitution approach, 245 transitioning opioids to cannabis [38]; Two studies focused on physical interventions, 246 incorporating components such as yoga, Taichi, chiropractic therapy [34] and 247 acupuncture [35]; Five studies involved psychological or behavioral changes, 248 integreting key components such as cognitive behavior therapy (CBT), mindfulness 249 techniques, patient education and pain coping skills training [28-30, 32, 33]; Three 250 studies [31, 36, 37] employed mixed multimodal approaches delivered by a 251 multidisciplinary team comprising physicians, nurses, psychologists, pharmacists, and 252 social workers. These multimodal care programs typically combined CBT, mindfulness, 253 acupuncture, chiropractic care, exercise, pharmacotherapies are the core components.

254

The most common comparator was usual care, with the exception of one study that used patient education as the comparison group [38]. Treatment durations ranged from eight weeks to 12 months. Follow-up periods (median 6 months) varied from short (\leq 3 months) [28, 29] to intermediate (6-9 \square months) [31, 33-37], with three studies reporting long-term outcomes of opioid reduction (\geq 12 \square months) . (See Table 2 for characteristics of interventions).

Table 2. The components and implementation procedures of each intervention

Studies	Interventions	Duration	Implemented by			
Pharmacological substitution (n=1)						
Vigil <i>et al.</i> 2017 [38]	Medical cannabis & patient education	21 months	Physicians			
Physical procedure (n=2)						
Montgomery et al. 2020 [35]	Battlefield Acupuncture: 5-point auricular acupuncture procedure implemented	9 months	Physicians			
Mehl-Madrona <i>et al.</i> 2016 [34]	Twice monthly GMV (12 sessions) & weekly physical activity (yoga, exercise class, chiropractic therapy, osteopathic treatment, tai chi, or qigong)	6 months	Family doctor, nurse, and behavioral health specialist			
Psychological or behavioral int	ervention (n=5)					
Sandhu <i>et al.</i> 2023 [30]	Weekly skill-based learning and education including mindfulness, relaxation, opioid education, consultation and followed by an opioid taper (weekly 10% reduction)	12 months	Nurse			
Wartko <i>et al.</i> 2023 [32]	CBT-based pain coping skill training: 18 sessions (30 min for each on average), mainly including pain education, goal setting, relaxation skills and motivational interviews, conducted over one year.	12 months	Primary care provider, nurse, physician assistant			
Hudak <i>et al.</i> 2021 [29]	The MORE protocol: 2-hour weekly training sessions in mindfulness, reappraisal and savoring pleasant events & a 15-min CD-guided mindfulness practice at home and 3-minute breathing before taking opioids	4 months	Clinical social workers			
Garland <i>et al.</i> 2020 [28]	The MORE protocol: 2-hour weekly training sessions in mindfulness, reappraisal and savoring pleasant events & a 15-min CD-guided mindfulness practice at home and 3-minute breathing before taking opioids	3 months	Clinical social workers			
Goodman <i>et al.</i> 2018 [33]	Family physician-patient's discussion of pain management guidelines and practice followed by an opioid tapering program (weekly 10% reduction to 25%-50% reduction every few days)	6 months	Family physician			
Multimodalities (n=3)						
Sullivan <i>et al.</i> 2017 [31]	A weekly 10% reduction of the initial dose until 30% was reached. Then, a 10% was recalculated based on this dose and then proceeded by 10% of this new dose per week.) & 17 weekly 30-min consultations, CBT-modelled pain self-management,	8.5 months	Pain medicine/psychiatry physicians, psychologists and physician assistants			

Studies	Interventions	Duration	Implemented by
	education & a book/CD-guided home practice		
Oldfield <i>et al.</i> 2018 [36]	Multidisciplinary ORC program including pharmacotherapy, CBT and other modalities (e.g., acupuncture, chiropractic, and yoga)	6 months	Physicians, pain specialists, pain psychologists and chemical dependency counsellors
Seal <i>et al.</i> 2019 [37]	Integrated Pain Team: an initial 60-min's biopsychosocial model of pain management (including CBT, mindfulness, acupuncture, chiropractic care, and exercise) & a 30-min follow-up visits	6 months	Medical provider, psychologist, and pharmacist

262 Note: MORE=Mindfulness-Oriented Recovery Enhancement, CBT=Cognitive Behavioral Therapy, ORC=Opioid Reassessment Clinic, GMV=Group Medical Visits

263 Risk of bias assessment

264	The Cochrane RoB-2 assessment indicated an overall risk of bias being low (n=3) to
265	moderate (n=2) (Fig 2. Risk of Bias of included RCTs). Due to the impossibility of
266	masking the interventions, participants and researchers were unblinded, which
267	increased risk. The high dropout rate during follow-ups was another main reason
268	contributing to the increased risk of bias. The NOS evaluation tool identified three
269	cohort studies [34, 36, 37] with good quality, two [33, 38] with fair and one [35] with
270	poor quality (Table 3). Uncontrolled confounders and limited representativeness of
271	the study population were the main reasons that reduced the quality of these studies.

- 272
- 273

Table 3. Quality assessment outcomes of cohort studies

Three domains of the Newcastle-Ottawa Scale			awa Scale		
Author and year	Selection of participants	Comparability of study groups	Outcomes	Quality	
Montgomery et al. 2020 [35]	***	*	*	Poor	
Seal et al. 2019 [37]	****	**	***	Good	
Oldfield et al. 2018 [36]	***	**	***	Good	
Goodman et al. 2018 [33]	***	*	**	Fair	
Vigil <i>et al.</i> 2017 [38]	***	*	**	Fair	
Mehl-Madrona et al. 2016 [34]	***	**	***	Good	

274 **Opioid dose reduction**

275 Ten studies including four RCTs [28, 29, 31, 32] and six cohort studies [33-38] reported 276 the outcomes of opioid dose reduction. Opioid dosage was significantly decreased in 277 the intervention groups compared to controls (MD: -31.80 mg/day, 95%CI: -50.30 to -278 13.31; ten studies; Fig 3. Forest plot of interventions vs controls in opioid dose reduction in ten studies). However, considerable heterogeneity was noted ($I^2 = 91.14\%$, 279 280 95%CI: 80.4% to 96.0%, p=0.00; Fig 3). A sensitivity analysis was conducted to 281 investigate the source of heterogeneity and the Mehl-Madrone et al. (2016)'s study [34] 282 was identified as an outlier (Fig 4. Sensitivity analysis of included studies). Upon its removal, the heterogeneity decreased from high $(l^2 = 91.14\%)$ to medium $(l^2 = 1.14\%)$ 283 284 59.41%), but the significance or direction of the pooled effects in our meta-analyses 285 remained unchanged (MD: -24.88 mg; 95%Cl: -36.40 to -13.36; nine studies; Fig 5. 286 Forest plot of interventions vs controls in opioid dose reduction in nine studies). 287 Furthermore, a multivariable meta-regression analysis was conducted, revealing that 288 heterogeneity could be partially explained by differences in the longest follow-up time 289 across studies (p=0.014).

290

291 Within the four RCTs [28, 29, 31, 32] provided data that enabled the pooled calculation 292 of change for opioid reduction among 181 participants receiving different interventions compared to 162 receiving usual care (MD: -24.40 mg; 95%CI: -36.32 to -12.47; $l^2 =$ 293 294 9.21%, p=0.35; Fig 6. Forest plot of interventions vs controls in opioid dose reduction in 295 four RCTs), a subgroup meta-analysis of two trials [28, 29] using the MORE protocol 296 (mindfulness) found a significant reduction in opioid dosage in 84 patients receiving this 297 intervention, compared to 77 having supportive care (MD: -29.36 mg; 95%CI: -40.55 to 298 -18.17; $I^2 = 0.00\%$, p=0.37; Fig 6). Similar decreases in opioid dose were reported by 299 Wartko et al. (2023) [32] and Sullivan et al. (2017) [31] using CBT-based multi-300 component interventions. However, no between-group statistical significance was 301 attained (MD: -10.10 mg; 95%CI: -33.61 to 13.40; $l^2 = 0.00\%$, p=0.52; Fig 6).

\mathbf{r}	n	\mathbf{c}
J	υ	2

Within the six cohort studies [33-38], where various interventions were implemented, a significant decrease in the use of opioid medications was observed in the intervention groups (MD: -29.89 mg; 95%CI: -49.00 to -10.78; $l^2 = 72.72\%$, p=0.01; Fig 7. Forest plot of interventions vs controls in opioid dose reduction in five cohort studies). Subgroup analysis of Oldfield et al. (2018) and Seal et al. (2021) using CBT-based interventions showed a significant reduction in opioid dose, compared to those in the control group. (MD: -41.68 mg; 95%CI: -58.47 to -24.89; $l^2 = 0.00\%$, p=0.76; Fig 7).

310

311 **Opioid cessation**

312 No significant differences were observed in opioid cessation (Odds ratio: 1.55, 95%CI: 313 0.3 to 2.81; I2=50.79%, p=0.13; three studies; Fig 8. Forest plot of interventions vs 314 controls in opioid cessation) between intervention groups and controls. In the two RCTs 315 [30, 31], although the interventions had slight variations, both studies implemented a 316 weekly 10% dose reduction protocol combined with education and consultation as core components of the interventions. In the Sandhu et al. (2023) study [30], patients 317 318 undergoing skill-based learning and education had a significantly higher cessation rate 319 than those receiving usual care (Odds radio [OR]: 5.23; 95% CI 2.87 to 9.52; Fig 8.). 320 However, pooled meta-analysis showed no statistically significant change in opioid 321 discontinuation (OR: 1.10; 95%CI -0.48 to 2.67; Fig 8.). Moderate heterogeneity 322 (12=58.59%, 95% CI 0% to 86.2%) was observed, primarily attributed to the small 323 sample size of the Sullivan et al. (2017) study [31].

324

In the cohort study [38] reporting opioid cessation, where 37 patients received cannabis-assisted opioid replacement along with patient education. Among them, 15 patients completely discontinued the opioid use over a period of 21 months. When compared to a control group receiving education alone, the cessation rate of opioid was lower in the control group, with only 1 out of 29 patients achieving opioid cessation;

however, this difference was not statistically significant, primarily because of the very
small sample size (OR: 2.95, 95% CI 0.85 to 5.05; Fig 8).

332

333 Pain severity

334 Pain severity changes at different observation time points were reported in three trials 335 [30-32], all utilizing interventions grounded in behavior change and patient education. 336 Due to the variations in pain severity measurements across studies, standard mean 337 differences were used for pooling the estimates. While a decrease in pain severity was 338 observed in all three trials, the between-group difference was small and non-significant (SMD -0.13; 95% CI -0.37 to 0.11, I² =33.51%, p=0.22; Fig 9. Forest plot of 339 340 interventions vs controls in pain severity improvement). It is worth noting that this 0.13-341 point reduction in pain score might not have meaningful clinical implications.

342

343 Due to the poor study quality and high heterogeneity, meta-analysis was not feasible 344 for two cohort studies [35, 38] reporting the outcome of pain severity. Therefore, the 345 results were narratively reviewed. Compared with these behavioral, psychological and 346 physical interventions, the pharmacological intervention (cannabis) combined with 347 patient education, as used in the Vigil et al. (2017) study [38], showed a significant 348 decrease in pain intensity score (MD: -3.4 on a scale of 0-10, p<0.001), which 349 suggested a meaningful clinical implication. Acupuncture, as employed in the 350 Montgomery et al. (2020) study [35], exhibited an immediate effect in alleviating pain 351 (a reduction in pain intensity score of MD 1.3 on a scale of 0-10, p<0.01). However, 352 there were no significant differences after 9 months (p = 0.15), indicating acupuncture's 353 short-term effects.

354

355 Adverse events

Adverse events (AEs) were infrequently examined in included studies, with the majority
 of reported AEs being associated with psychological and nervous system effects. In

358 Wartko et al. (2023)'s study [32], which involved 79 participants receiving CBT-based 359 pain coping skills training plus usual care, six cases of increased pain, one case of 360 withdrawal symptoms, and one case of anxiety were noted. No serious adverse events 361 (SAEs) were documented in this study. In Sandhu et al. (2023) [30], adverse events 362 such as sleep disturbance, suicidal ideation, headache, withdrawal symptoms were 363 reported by 22 of 305 participants (7%) and 8 of 303 participants (3%), in the 364 intervention and usual care groups, respectively. SAEs occurred in 8% (25/305) of the 365 participants in the intervention group and 5% (16/303) in the usual care group, with the 366 most common SAEs being gastrointestinal disorder, metastatic cancer, hospitalization 367 due to increased pain, and unknown cause of death.

368

369 **Discussion**

370 Summary of main findings

371 In this systematic review and meta-analysis, we examined 11 studies (five RCTs and 372 six cohort studies) assessing the effectiveness of opioid reduction interventions for 373 patients with CNCP in primary healthcare settings. Despite methodological differences, 374 both RCTs and observational studies yielded statistically similar results, allowing for the 375 pooling of results across the full range of eligible studies. Overall, intervention groups 376 exhibited significant reductions in opioid dosage compared to usual care or active 377 control. Subgroup analyses revealed significant opioid dose reductions with 378 mindfulness and CBT-based multimodalities, respectively, compared to usual care. No 379 significant differences were observed in opioid cessation or pain severity. Adverse 380 events were infrequently examined, with withdrawal symptoms commonly reported. 381 Medium heterogeneity was observed across all studies for each outcome, likely 382 stemming from variability in interventions, follow-up durations, and healthcare providers involved. Nevertheless, the I² values for subgroup analyses were low. 383

384

385 **Compare with existing literature**

386 Our study conclusion generally aligns with previous systematic reviews [16-19] that the 387 strength of evidence was insufficient to draw conclusions. However, our study extends 388 these reviews by providing an updated and comprehensive assessment of the literature. 389 adding one recent good-quality RCT. Supported by subgroup meta-analyses, we 390 elucidated the effectiveness of mindfulness in reducing LTOT. Meanwhile, we 391 highlighted key components such as CBT, patient education, mindfulness, exercise, 392 which may contribute to the successful opioid reduction and thus merit consideration 393 for future intervention development. Importantly, our study exclusively targeted primary 394 care settings, distinguishing it from others that included secondary and tertiary care 395 settings. Although de Kleijn et al. (2021) [17] solely focused on primary care settings, 396 their results were narratively synthesized, and they included studies using simple 397 opioid tapering protocols or interventions targeted at physicians.

398

399 Clinical guidelines [11, 12] recommend an initial reduction of opioid dosage by 10% per 400 week, with adjustments for high-dose users (> MEDD 120 mg/day) or those on LTOT 401 exceeding one year [39]. In our study, we observed a pooled mean opioid reduction of 402 24.88 mg/day from a baseline of 87.4 mg/day. Although this reduction was aggressive 403 and exceeded the guideline-recommended reduction rate, it did yield a clinically 404 meaningful decrease in opioid dosage without worsening pain severity. It is important to 405 acknowledge that adherence to guideline recommendations does not necessarily 406 guarantee optimal patient outcomes, as individual responses to opioid reduction 407 strategies may vary. In fact, the primary goal of CNCP management is to maintain body 408 function rather than achieve complete pain eradiation. Therefore, efforts should 409 prioritize reducing opioids to minimize potential harms associated with LTOT. 410 Meanwhile, despite limited examination of adverse events in this study, our findings 411 align with existing evidence [40, 41], suggesting that opioid reduction may lead to 412 withdrawal symptoms, increased pain severity, suicides or all-cause mortality.

413 Therefore, close monitoring of patient responses to opioid reduction strategies is414 essential for optimizing treatment outcomes while mitigating adverse effects.

415

416 Our findings highlighted the effectiveness of the MORE protocol, with mindfulness as 417 its core component, in reducing opioid dose for CNCP patients in the short term (3 418 Additionally, meta-analytic results indicated a significant and strong months). 419 association between mindfulness and pain reduction [42]. In another study [43] 420 conducted by the same author using the MORE protocol, participants reported 421 significantly greater improvements in psychological and physical function outcomes 422 (e.g., general activity, mood, walking ability, normal work, relationships, sleep, and 423 enjoyment of life.) compared to the support group during the three-month follow-up 424 period. In view of this evidence, mindfulness could be considered a potential 425 component in the development of opioid reduction strategies. However, before 426 recommending widespread implementation of this intervention, further validation 427 through replication in a second trial with a longer observation period (≥12 months) 428 within primary care settings is necessary.

429

430 Contrary to expectations, CBT-based interventions did not show a significant reduction 431 in opioid dosage in RCTs [31, 32]. This finding aligns with recent evidence from a 432 recent cluster RCT, indicating that although CBT significantly reduced pain severity, it 433 did not result in significant differences in opioid use between groups [43]. The reason 434 for this non-significant result may be twofold. First, the small sample size and variations 435 in interventions across studies may have contributed to the lack of statistical 436 significance. Second, the study conducted by Sullivan et al. (2017) [31] involved high-437 dose users (207±245 mg/day), suggesting that behavior changes might not be superior 438 to usual care in reducing opioids dosage for this population. However, the pain relief 439 achieved through CBT may contribute to a subsequent decrease in opioid utilization, 440 although this effect may take time to manifest. Two observational studies [36, 37]

employing similar CBT-based interventions reported significant reductions in opioid dosage compared to usual care. This inconsistency with findings from RCTs may be attributed to the variations in interventions. Additionally, observational studies may yield more promising results due to unadjusted confounders. Further investigation with longterm follow-up and larger sample sizes is warranted to elucidate the effects of CBT on opioid reduction.

447

448 Pharmacological interventions (cannabis-assisted opioid substitution) showed 449 promising result, with a higher rate of opioid cessation and improved pain severity 450 observed among the study population. This could be explained by the fact that patients 451 often perceive pharmacotherapies as providing immediate pain relief, contrasting with 452 non-pharmacological approaches which may require more time to yield noticeable 453 effects. Consequently, patients may be more inclined towards pharmacological 454 treatments, especially during episodes of exacerbated pain. This preference may be 455 influenced by patients' desire to promptly alleviate pain [44], and the challenges 456 associated with accessing non-pharmacological therapies [45], which further 457 perpetuates the reliance on pharmacotherapy in managing CNCP symptoms. While 458 cannabis demonstrates efficacy in replacing opioids for CNCP management, its long-459 term use may pose potential risks, including lower educational achievement, 460 psychiatric illness, and residual cognitive impairment [46]. Therefore, careful 461 consideration and monitoring are necessary when utilizing cannabis as a substitute for 462 opioids in CNCP management.

463

464 Current clinical guidelines from the UK NICE (National Institute for Health and Care 465 Excellence) [13, 47] and NHS Oxford Hospital [12] advocate for a holistic approach 466 beyond pharmacotherapy alone. Our research findings align with these 467 recommendations, revealing that a combination of cognitive change strategies, 468 acupuncture, exercise, patient education and pharmacotherapies, delivered by a

469 multidisciplinary team were more effective in opioid reduction. Central to this success is 470 the practice of shared decision making between patient and healthcare professionals. 471 The collaboration among diverse healthcare professionals (GPs, nurses, therapists, pharmacists, etc) is crucial, as each contributes unique expertise and insights to the 472 473 table. Nevertheless, challenges remain in accessing to multimodal cares, particularly 474 for individuals unable to take time off work, those residing in regions with limited 475 services, and individuals from culturally and linguistically diverse communities. 476 Addressing these access barriers is essential to ensuring equitable healthcare delivery.

477

478 Strengths and limitations

479 To our knowledge, this is the first and most up-to-date systematic review and meta-480 analysis, to evaluate the effectiveness of interventions on opioid dose reduction and 481 pain outcomes for patients with CNCP, with a particular emphasis on primary 482 healthcare settings. By conducting a comprehensive literature search and including 483 recently conducted studies in the UK, this research holds informative value for the 484 potential implementation of interventions outside the US primary care settings. 485 Moreover, several key subgroup analyses were conducted to identify which intervention 486 (components) are effective in achieving opioid reduction purpose.

487

488 Our study also had several limitations. First, the relatively small number of included 489 participants, short follow-up periods, and lack of blinding to interventions may have 490 introduced biases and impacted the overall quality of the included studies. Second, 491 data in observational studies were sourced from secondary databases or electronic 492 medical records, which could cause information bias. Third, funnel plots and the 493 Egger's test were not performed due to the small number of studies included in the 494 meta-analyses Fourth, the majority of the studies were conducted on white populations 495 in the US, likely influenced by the opioid crisis in that country, thus limited the 496 generalizability of our research findings to other ethnicities and regions. Lastly, data

497 was insufficient to support meta-analyses of quality of life or function.

498

499 Conclusion

500 Although according to prior studies, no specific interventions can be recommended 501 over one another, multidisciplinary opioid reduction strategies, incorporating 502 components such as CBT, pain education, mindfulness, exercise and acupuncture, 503 have demonstrated effectiveness and tolerability in reducing opioid doses and 504 improving pain severity among patients with CNCP in primary care settings. However, 505 robust evidence remains limited due to several factors, including a shortage of well-506 designed research studies, inadequate long-term follow-up periods and absence of 507 QoL-related outcomes. Future studies should prioritize investigating the active 508 components within these interventions to gain a deeper understanding of the specific 509 strategies contributing to positive outcomes. Additionally, it is essential to assess the 510 cost-effectiveness and patient acceptability of these interventions before their 511 implementation in specific primary care contexts.

512

513 Acknowledgments

514 None.

515

516 Contributors

- 517 Conceptualization: LCC, EK, QC, TCC.
- 518 Data curation: QC, CG, TCC, EK.
- 519 Formal analysis: QC, EK.
- 520 Investigation: QC, CG, TCC.
- 521 Methodology: QC, EK.
- 522 Project administration: QC.
- 523 Supervision: EK TA CG LCC.
- 524 Validation: CG TCC.

- 525 Visualization: QC.
- 526 Writing original draft: QC.
- 527 Writing review & editing: QC CG TA TCC LCC EK.
- 528
- 529 Funding source
- 530 None.

References

- 1. Anekar, A.A. and M. Cascella, *WHO analgesic ladder.* 2020.
- 2. Boudreau, D., et al., *Trends in long-term opioid therapy for chronic non-cancer pain.* Pharmacoepidemiology and drug safety, 2009. **18**(12): p. 1166-1175.
- 3. Smolina, K., et al., *Patterns and trends in long-term opioid use for non-cancer pain in British Columbia, 2005–2012.* Canadian Journal of Public Health, 2016. **107**: p. e404-e409.
- 4. Werber, A., et al., *Opioid therapy in the treatment of chronic pain conditions in Germany.* Pain Physician, 2015. **18**(3): p. E323.
- 5. Kalkman, G., et al., *Practice variation in opioid prescribing for non-cancer pain in Dutch primary care: A retrospective database study.* Plos one, 2023. **18**(2): p. e0282222.
- 6. Hansen, C.A., et al., *Epidemiological Factors Associated with Prescription of Opioids for Chronic Non-Cancer Pain in Adults: A Country-Wide, Registry-Based Study in Denmark Spans 2004–2018.* Journal of Pain Research, 2023: p. 463-485.
- 7. Jani, M., et al., *Time trends and prescribing patterns of opioid drugs in UK primary care patients with non-cancer pain: a retrospective cohort study.* PLoS Medicine, 2020. **17**(10): p. e1003270.
- 8. Busse, J.W., et al., Opioids for chronic noncancer pain: a systematic review and metaanalysis. Jama, 2018. **320**(23): p. 2448-2460.
- 9. Gomes, T., et al., *The burden of opioid-related mortality in the United States.* JAMA network open, 2018. **1**(2): p. e180217-e180217.
- Edlund, M.J., et al., *Risks for opioid abuse and dependence among recipients of chronic opioid therapy: results from the TROUP study.* Drug and alcohol dependence, 2010. **112**(1-2): p. 90-98.
- 11. Dowell, D., T.M. Haegerich, and R. Chou, *CDC guideline for prescribing opioids for chronic pain—United States, 2016.* Jama, 2016. **315**(15): p. 1624-1645.
- 12. NHS Oxford University Hospital. Guidance for opioid reduction in primary care. <u>https://www.ouh.nhs.uk/services/referrals/pain/documents/gp-guidance-opioid-reduction.pdf</u> [Accessed on 04 Feb 2024].
- 13. NICE. Chronic Pain, management. 2021. Available from: <u>https://cks.nice.org.uk/topics/chronic-pain/management/management/</u>. [cited on Feb 7th 2024].
- 14. Cross, A.J., et al., Barriers and enablers to monitoring and deprescribing opioid analgesics for chronic non-cancer pain: a systematic review with qualitative evidence synthesis using the Theoretical Domains Framework. BMJ Quality & Safety, 2022. **31**(5): p. 387-400.
- 15. Frank, J.W., et al., *Patients' perspectives on tapering of chronic opioid therapy: a qualitative study.* Pain medicine, 2016. **17**(10): p. 1838-1847.
- 16. Avery, N., et al., *Efficacy of interventions to reduce long term opioid treatment for chronic non-cancer pain: systematic review and meta-analysis.* Bmj, 2022. **377**.
- 17. de Kleijn, L., et al., *Opioid reduction for patients with chronic pain in primary care: systematic review.* British Journal of General Practice, 2022.
- 18. Frank, J.W., et al., *Patient outcomes in dose reduction or discontinuation of long-term opioid therapy: a systematic review.* Annals of internal medicine, 2017. **167**(3): p. 181-191.
- 19. Mathieson, S., et al., *Deprescribing opioids in chronic non-cancer pain: systematic review of randomised trials.* Drugs, 2020. **80**(15): p. 1563-1576.
- 20. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from <u>www.training.cochrane.org/handbook</u>.
- 21. Page, M.J., et al., *The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.* International Journal of Surgery, 2021. **88**: p. 105906.
- 22. Sterne, J.A., et al., *RoB 2: a revised tool for assessing risk of bias in randomised trials.* bmj, 2019. **366**.
- 23. Wells, G.A., et al., *The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.* 2000, Oxford.
- 24. Borenstein, M., et al., *A basic introduction to fixed-effect and random-effects models for meta -analysis.* Research synthesis methods, 2010. **1**(2): p. 97-111.
- 25. Higgins, J.P. and S. Green, Cochrane handbook for systematic reviews of interventions. 2008.
- 26. Kontopantelis, E., D.A. Springate, and D. Reeves, A re-analysis of the Cochrane Library data:

the dangers of unobserved heterogeneity in meta-analyses. PloS one, 2013. 8(7): p. e69930.

- Petropoulou, M. and D. Mavridis, A comparison of 20 heterogeneity variance estimators in statistical synthesis of results from studies: a simulation study. Statistics in medicine, 2017. 36(27): p. 4266-4280.
- Garland, E.L., et al., Mindfulness-oriented recovery enhancement reduces opioid dose in primary care by strengthening autonomic regulation during meditation. American Psychologist, 2020. 75(6): p. 840.
- 29. Hudak, J., et al., Endogenous theta stimulation during meditation predicts reduced opioid dosing following treatment with Mindfulness-Oriented Recovery Enhancement. Neuropsychopharmacology, 2021. **46**(4): p. 836-843.
- 30. Sandhu, H.K., et al., *Reducing opioid use for chronic pain with a group-based intervention: a randomized clinical trial.* JAMA, 2023. **329**(20): p. 1745-1756.
- 31. Sullivan, M.D., et al., *Prescription opioid taper support for outpatients with chronic pain: a randomized controlled trial.* The journal of pain, 2017. **18**(3): p. 308-318.
- 32. Wartko, P.D., et al., STRategies to Improve Pain and Enjoy life (STRIPE): results of a pragmatic randomized trial of pain coping skills training and opioid medication taper guidance for patients on long-term opioid therapy. Pain, 2023.
- 33. Goodman, M.W., T.P. Guck, and R.M. Teply, *Dialing back opioids for chronic pain one conversation at a time*. J Fam Pract, 2018. **67**(12): p. 753-757.
- 34. Mehl-Madrona, L., B. Mainguy, and J. Plummer, *Integration of complementary and alternative medicine therapies into primary-care pain management for opiate reduction in a rural setting.* The Journal of Alternative and Complementary Medicine, 2016. **22**(8): p. 621-626.
- 35. Montgomery, A.D. and R. Ottenbacher, *Battlefield acupuncture for chronic pain management in patients on long-term opioid therapy.* Medical Acupuncture, 2020. **32**(1): p. 38-44.
- Oldfield, B.J., et al., Multimodal treatment options, including rotating to buprenorphine, within a multidisciplinary pain clinic for patients on risky opioid regimens: A quality improvement study. Pain Medicine, 2018. 19(suppl_1): p. S38-S45.
- 37. Seal, K.H., et al., Opioid reduction and risk mitigation in VA primary care: Outcomes from the integrated pain team initiative. Journal of general internal medicine, 2020. **35**: p. 1238-1244.
- 38. Vigil, J.M., et al., Associations between medical cannabis and prescription opioid use in chronic pain patients: a preliminary cohort study. PloS one, 2017. **12**(11): p. e0187795.
- 39. Chou, R., et al., Best practices, research gaps, and future priorities to support tapering patients on long-term opioid therapy for chronic non-cancer pain in outpatient settings. NAM perspectives, 2020. **2020**.
- 40. Hallvik, S.E., et al., *Patient outcomes after opioid dose reduction among patients with chronic opioid therapy.* Pain, 2022. **163**(1): p. 83-90.
- 41. Metz, V.E., et al., *Prescription opioid dose reductions and potential adverse events: a multisite observational cohort study in diverse US health systems.* Journal of general internal medicine, 2023: p. 1-8.
- 42. Garland, E.L., et al., *Mind-body therapies for opioid-treated pain: A systematic review and meta-analysis.* JAMA internal medicine, 2020. **180**(1): p. 91-105.
- 43. Garland, E.L., E. Thomas, and M.O. Howard, *Mindfulness-oriented recovery enhancement* ameliorates the impact of pain on self-reported psychological and physical function among opioid-using chronic pain patients. Journal of pain and symptom management, 2014. **48**(6): p. 1091-1099.
- 44. Lewis, P.J., *Uncomfortable Prescribing Decisions in Secondary Care.* 2007, The University of Manchester (United Kingdom): Ann Arbor. p. 302.
- 45. Elsharydah, A., J. Wu, and F.C. Li, *Decreasing waiting time for new patients at a community pain clinic*. Proc (Bayl Univ Med Cent), 2022. **35**(3): p. 315-318.
- 46. Iversen, L., *Long-term effects of exposure to cannabis.* Current opinion in Pharmacology, 2005. **5**(1): p. 69-72.
- 47. NICE. Analgesics. 2022. Available from: <u>https://bnf.nice.org.uk/treatment-</u> <u>summaries/analgesics/</u>. [Cited on 2024 Feb 7th].